Company news

Share this article:

Japanese drugmaker Astellas Pharma said it will set up a new company in Illinois in April to oversee the clinical development activities of its group as a whole. The transfer of Astellas' clinical development base, currently located in Japan, is aimed at speeding up decision-making and boosting market competitiveness, the company said. The new firm will be named Astellas Pharma Global Development Inc. Recently, a growing number of Japanese drugmakers have transferred their research and development bases to locations outside Japan, reflecting a slowdown in the domestic market and increased dependence on overseas sales.

Merck said that 44,000 of the roughly 47,000 people who registered for shares of a $4.85 billion settlement over the withdrawn painkiller Vioxx settlement have submitted all or some of the paperwork necessary for enrollment in the deal. Those who enrolled in the settlement by this past Friday could be eligible to receive an interim payment later this year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.